Bench-to-bedside review: The role of β-lactamases in antibiotic-resistant Gram-negative infections

Critical Care

Volumn 14, Issue 3, 2010, Pages

  Bush, Karen ^a  

^a INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AZTREONAM; BACTERIAL ENZYME; BETA LACTAMASE; BETA LACTAMASE CTX M; CARBAPENEM; CEFDINIR; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFPODOXIME; CEFPROZIL; CEFTAZIDIME; CEFTRIAXONE; CEFUROXIME AXETIL; CEPHALOSPORIN; DORIPENEM; ERTAPENEM; IMIPENEM; MEROPENEM; METALLO BETA LACTAMASE; MONOBACTAM; PENICILLIN G; PENICILLINASE; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TIMENTIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL MENINGITIS; BACTERIAL STRAIN; BACTERIUM ISOLATION; ENTEROBACTERIACEAE INFECTION; GONORRHEA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HOSPITAL INFECTION; HUMAN; HYDROLYSIS; KLEBSIELLA PNEUMONIAE; LOWER RESPIRATORY TRACT INFECTION; MULTIDRUG RESISTANCE; NONHUMAN; OSTEOMYELITIS; OTITIS MEDIA; PLASMID; PNEUMONIA; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RESERVOIR; REVIEW; SKIN INFECTION; URINARY TRACT INFECTION; DRUG EFFECT; METABOLISM;

BETA-LACTAMASES; DRUG RESISTANCE, BACTERIAL; GRAM-NEGATIVE BACTERIA; HUMANS;

EID: 79952111025     PISSN: 13648535     EISSN: 1466609X     Source Type: Journal    
DOI: 10.1186/cc8892     Document Type: Review

References (64)

1. Chambers HF, Deleo FR. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat Rev Microbiol 2009, 7:629-641. 19680247, 10.1038/nrmicro2200, 2871281.
2. Abbanat D, Morrow B, Bush K. New agents in development for the treatment of bacterial infections. Curr Opin Pharmacol 2008, 8:582-592. 10.1016/j.coph.2008.08.001, 18761107.
3. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad bugs, no drugs: No ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009, 48:1-12. 10.1086/595011, 19035777.
4. Gilbert DN, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS, . (Eds) The Sanford Guide to Antimicrobial Therapy 2009. 2009, Sperryville, VA: Antimicrobial Therapy, Inc, 39, (Eds).
5. Abraham EP, Chain E. An enyzme from bacteria able to destroy penicillin. 1940. Rev Infect Dis 1988, 10:677-678. 3055168, 10.1038/146837a0.
6. Jacoby GA, Bush K. Amino acid sequences for TEM, SHV and OXA extended-spectrum and inhibitor resistant β-lactamases. 2009, http://www.lahey.org/Studies/
7. Bush K, Jacoby GA. An updated functional classification of β-lactamases. Antimicrob Agents Chemother 2010, 54:969-976. 10.1128/AAC.01009-09, 19995920.
8. Ambler RP. The structure of β-lactamases. Philos Trans R Soc Lond B Biol Sci 1980, 289:321-331. 10.1098/rstb.1980.0049, 6109327.
9. Jaurin B, Grundstrom T. ampC cephalosporinase of Escherichia coli K-12 has a different evolutionary origin from that of β-lactamases of the penicillinase type. Proc Natl Acad Sci USA 1981, 78:4897-4901. 320287, 6795623, 10.1073/pnas.78.8.4897.
10. Huovinen P, Huovinen S, Jacoby GA. Sequence of PSE-2 beta-lactamase. Antimicrob Agents Chemother 1988, 32:134-136. 172114, 3126705.
11. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for β-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995, 39:1211-1233. 162717, 7574506.
12. Choi SH, Lee JE, Park SJ, Lee SO, Jeong JY, Kim MN, Woo JH, Kim YS. Emergence of antibiotic resistance during therapy for infections caused by Enterobacteriaceae producing Ampc beta-lactamase: implications for antibiotic use. Antimicrob Agents Chemother 2008, 52:995-1000. 2258504, 18086837, 10.1128/AAC.01083-07.
13. Livermore DM, Brown DF, Quinn JP, Carmeli Y, Paterson DL, Yu VL. Should third-generation cephalosporins be avoided against AmpC-inducible Enterobacteriaceae?. Clin Microbiol Infect 2004, 10:84-85. 10.1111/j.1469-0691.2004.00831.x, 14706093.
14. Goldstein FW. Cephalosporinase induction and cephalosporin resistance: a longstanding misinterpretation. Clin Microbiol Infect 2002, 8:823-825. 10.1046/j.1469-0691.2002.00492.x, 12519358.
15. Chow JW, Fine MJ, Shlaes DM, Quinn JP, Hooper DC, Johnson MP, Ramphal R, Wagener MM, Miyashiro DK, Yu VL. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Int Med 1991, 115:585-590.
16. Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing; Twentieth Informational Supplement. CLSI document M100-S20 2010, Wayne, PA: Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute.
17. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev 2009, 22:161-182. 2620637, 19136439, 10.1128/CMR.00036-08.
18. Perine PL, Schalla W, Siegel MS, Thornsberry C, Biddle J, Wong K-H, Thompson SE. Evidence for two distinct types of penicillinase-producing Neisseria gonorrhoeae. Lancet 1977, 2:993-997. 10.1016/S0140-6736(77)92891-4, 72949.
19. Scriver SR, Walmsley SL, Kau CL, Hoban DJ, Brunton J, McGeer A, Moore TC, Witwicki E. Determination of antimicrobial susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their beta-lactamases. Canadian Haemophilus study group. Antimicrob Agents Chemother 1994, 38:1678-1680. 284617, 7979309.
20. Medeiros AA. Beta-lactamases. Br Med Bull 1984, 40:18-27.
21. Roy C, Foz A, Segura C, Tirado M, Fuster C, Reig R. Plasmid-determined β-lactamases identified in a group of 204 ampicillin-resistant Enterobacteriaceae. J Antimicrob Chemother 1983, 12:507-510. 10.1093/jac/12.5.507, 6608515.
22. Sirot J, Chanal C, Petit A, Sirot D, Labia R, Gerbaud G. Klebsiella pneumoniae and other Enterobacteriaceae producing novel plasmid-mediated β-lactamaes markedly active against third-generation cephalosporins: epidemiological studies. Rev Infect Dis 1988, 10:850-859.
23. Jacoby GA, Medeiros AA, O'Brien TF, Pinto ME, Jiang H. Broad-spectrum, transmissible β-lactamases. N Engl J Med 1988, 319:723-723.
24. Quinn JP, Miyashiro D, Sahm D, Flamm R, Bush K. Novel plasmid-mediated β-lactamase (TEM-10) conferring selective resistance to ceftazidime and aztreonam in clinical isolates of Klebsiella pneumoniae. Antimicrob Agents Chemother 1989, 33:1451-1456. 172682, 2684007.
25. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Int Med 1993, 119:353-358.
26. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille-Michaud A, Perroux R, Cluzel R. Transferable resistance to third-generation cephalosporins in clinical isolates of Klebsiella pneumoniae: identification of CTX-1, a novel β-lactamase. J Antimicrob Chemother 1987, 20:323-334. 10.1093/jac/20.3.323, 3316146.
27. Kitzis MD, Billot-Klein D, Goldstein FW, Williamson R, Nhieu GTV, Carlet J, Acar JF, Gutmann L. Dissemination of the novel plasmid-mediated β-lactmase CTX-1, which confers resistance to broad spectrum cephalosporins, and its inhibition by β-lactamase inhibitors. Antimicrob Agents Chemother 1988, 32:9-14. 172088, 2831817.
28. Bauernfeind A, Grimm H, Schweighart S. A new plasmidic cefotaximase in a clinical isolate of Escherichia coli. Infection 1990, 18:294-298. 10.1007/BF01647010, 2276823.
29. Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas JM. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other beta-lactamases. Antimicrob Agents Chemother 1996, 40:509-513. 163149, 8834913.
30. Hawkey PM. Prevalence and clonality of extended-spectrum beta-lactamases in Asia. Clin Microbiol Infect 2008, 14(Suppl 1):159-165. 10.1111/j.1469-0691.2007.01855.x, 18154540.
31. Livermore DM, Canton R, Gniadkowski M, Nordmann P, Rossolini GM, Arlet G, Ayala J, Coque TM, Kern-Zdanowicz I, Luzzaro F, Poirel L, Woodford N. CTX-M: Changing the face of ESBLs in Europe. J Antimicrob Chemother 2007, 59:165-174. 10.1093/jac/dkl483, 17158117.
32. Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum beta-lactamases in South America. Clin Microbiol Infect 2008, 14(Suppl 1):154-158. 10.1111/j.1469-0691.2007.01869.x, 18154539.
33. Bush K. Extended-spectrum beta-lactamases in North America, 1987-2006. Clin Microbiol Infect 2008, 14(Suppl 1):134-143. 10.1111/j.1469-0691.2007.01848.x, 18154537.
34. Lewis JS, Herrera M, Wickes B, Patterson JE, Jorgensen JH. First report of the emergence of CTX-M-type extended-spectrum beta-lactamases (ESBLs) as the predominant ESBL isolated in a U.S. Health care system. Antimicrob Agents Chemother 2007, 51:4015-4021. 2151438, 17724160, 10.1128/AAC.00576-07.
35. Castanheira M, Mendes RE, Rhomberg PR, Jones RN, Castanheira M, Mendes RE, Rhomberg PR, Jones RN. Rapid emergence of blaCTX-M among Enterobacteriaceae in U.S. Medical centers: molecular evaluation from the MYSTIC program (2007). Microb Drug Resist 2008, 14:211-216. 18707552, 10.1089/mdr.2008.0827.
36. Cartelle M, del Mar Tomas M, Molina F, Moure R, Villanueva R, Bou G. High-level resistance to ceftazidime conferred by a novel enzyme, CTX-M-32, derived from CTX-M-1 through a single Asp240-Gly substitution. Antimicrob Agents Chemother 2004, 48:2308-2313. 415568, 15155242, 10.1128/AAC.48.6.2308-2313.2004.
37. Kimura S, Ishii Y, Tateda K, Yamaguchi K. Predictive analysis of ceftazidime hydrolysis in CTX-M-type beta-lactamase family members with a mutational substitution at position 167. Int J Antimicrob Agents 2007, 29:326-331. 10.1016/j.ijantimicag.2006.09.014, 17258896.
38. Walther-Rasmussen J, Hoiby N. OXA-type carbapenemases. J Antimicrob Chemother 2006, 57:373-383. 10.1093/jac/dki482, 16446375.
39. Walsh TR, Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008, 21:367-371. 10.1097/QCO.0b013e328303670b, 18594288.
40. Hujer KM, Hujer AM, Hulten EA, Bajaksouzian S, Adams JM, Donskey CJ, Ecker DJ, Massire C, Eshoo MW, Sampath R, Thomson JM, Rather PN, Craft DW, Fishbain JT, Ewell AJ, Jacobs MR, Paterson DL, Bonomo RA. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. Isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006, 50:4114-4123. 1694013, 17000742, 10.1128/AAC.00778-06.
41. Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007, 20:440-458. 1932750, 17630334, 10.1128/CMR.00001-07.
42. Yigit H, Queenan AM, Rasheed JK, Biddle JW, Domenech-Sanchez A, Alberti S, Bush K, Tenover FC. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing beta-lactamase KPC-2. Antimicrob Agents Chemother 2003, 47:3881-3889. 296202, 14638498, 10.1128/AAC.47.12.3881-3889.2003.
43. Kitchel B, Rasheed JK, Patel JB, Srinivasan A, Navon-Venezia S, Carmeli Y, Brolund A, Giske CG. Molecular epidemiology of KPC-producing Klebsiella pneumoniae isolates in the United States: clonal expansion of multilocus sequence type 258. Antimicrob Agents Chemother 2009, 53:3365-3370. 2715580, 19506063, 10.1128/AAC.00126-09.
44. Robledo IE, Aquino EE, Santé MI, Santana JL, Otero DM, León CF, Vázquez GJ. Detection of KPC in Acinetobacter sp. in Puerto Rico. Antimicrob Agents Chemother 2010, 54:1354-1357. 10.1128/AAC.00899-09, 20038618.
45. Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991, 35:147-151. 244956, 1901695.
46. Rahal JJ, Urban C, Horn D, Freeman K, Segal-Maurer S, Maurer J, Mariano N, Marks S, Burns JM, Dominick D, Lim M. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 280:1233-1237. 10.1001/jama.280.14.1233, 9786372.
47. Go ES, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N, Mosinka-Snipas K, Rahal JJ. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet 1994, 344:1329-1332. 10.1016/S0140-6736(94)90694-7, 7968028.
48. Kochar S, Sheard T, Sharma R, Hui A, Tolentino E, Allen G, Landman D, Bratu S, Augenbraun M, Quale J. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009, 30:447-452. 10.1086/596734, 19301985.
49. Nicolas-Chanoine MH, Blanco J, Leflon-Guibout V, Demarty R, Alonso MP, Canica MM, Park YJ, Lavigne JP, Pitout J, Johnson JR. Intercontinental emergence of Escherichia coli clone o25:H4-st131 producing CTX-M-15. J Antimicrob Chemother 2008, 61:273-281. 10.1093/jac/dkm464, 18077311.
50. Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenemhydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005, 49:4423-4424. 1251528, 16189140, 10.1128/AAC.49.10.4423-4424.2005.
51. Mendes RE, Spanu T, Deshpande L, Castanheira M, Jones RN, Fadda G. Clonal dissemination of two clusters of Acinetobacter baumannii producing OXA-23 or OXA-58 in Rome, Italy. Clin Microbiol Infect 2009, 15:588-592. 10.1111/j.1469-0691.2009.02770.x, 19438644.
52. Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N, Lu P-L, Doumith M, Livermore DM, Chen T-P, Woodford N. Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: Spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother 2009, 63:641-647. 10.1093/jac/dkn553, 19182237.
53. Moland ES, Hong SG, Thomson KS, Larone DH, Hanson ND. A Klebsiella pneumoniae isolate producing at least eight different beta-lactamases including an AmpC and KPC beta-lactamase. Antimicrob Agents Chemother 2007, 51:800-801. 1797768, 17145795, 10.1128/AAC.01143-06.
54. Giakkoupi P, Pappa O, Polemis M, Vatopoulos AC, Miriagou V, Zioga A, Papagiannitsis CC, Tzouvelekis LS. Emerging Klebsiella pneumoniae isolates coproducing KPC-2 and VIM-1 carbapenemases. Antimicrob Agents Chemother 2009, 53:4048-4050. 2737892, 19581459, 10.1128/AAC.00690-09.
55. Lee K, Kim MN, Choi TY, Cho SE, Lee S, Whang DH, Yong D, Chong Y, Woodford N, Livermore DM, Group K. Wide dissemination of OXA-type carbapenemases in clinical Acinetobacter spp. isolates from South Korea. Int J Antimicrob Agents 2009, 33:520-524. 10.1016/j.ijantimicag.2008.10.009, 19091520.
56. Elemam A, Rahimian J, Mandell W. Infection with panresistant Klebsiella pneumoniae: a report of 2 cases and a brief review of the literature. Clin Infect Dis 2009, 49:271-274. 19527172, 10.1086/600042.
57. Miriagou V, Tzelepi E, Daikos GL, Tassios PT, Tzouvelekis LS. Panresistance in VIM-1-producing Klebsiella pneumoniae. J Antimicrob Chemother 2005, 55:810-811. 10.1093/jac/dki080, 15772141.
58. Kimura S, Alba J, Shiroto K, Sano R, Niki Y, Maesaki S, Akizawa K, Kaku M, Watanuki Y, Ishii Y, Yamaguchi K. Clonal diversity of metallo-beta-lactamase-possessing Pseudomonas aeruginosa in geographically diverse regions of Japan. J Clin Microbiol 2005, 43:458-461. 540103, 15635015, 10.1128/JCM.43.1.458-461.2005.
59. Rossolini GM, Luzzaro F, Migliavacca R, Mugnaioli C, Pini B, Luca FD, Perilli M, Pollini S, Spalla M, Amicosante G, Toniolo A, Pagani L. First countrywide survey of acquired metallo-β-lactamases in gram-negative pathogens in Italy. Antimicrob Agents Chemother 2008, 52:4023-4029. 2573113, 18809945, 10.1128/AAC.00707-08.
60. Wiener J, Quinn JP, Bradford PA, Goering RV, Nathan C, Bush K, Weinstein RA. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999, 281:517-523. 10.1001/jama.281.6.517, 10022107.
61. Pitout JDD, Gregson DB, Church DL, Elsayed S, Laupland KB. Community-wide outbreaks of clonally related CTX-M-14 beta-lactamase-producing Escherichia coli strains in the Calgary health region. J Clin Microbiol 2005, 43:2844-2849. 1151948, 15956407, 10.1128/JCM.43.6.2844-2849.2005.
62. Munoz-Price LS. Long-term acute care hospitals. Clin Infect Dis 2009, 49:438-443. 10.1086/600391, 19548836.
63. Urban C, Bradford PA, Tuckman M, Segal-Maurer S, Wehbeh W, Grenner L, Colon-Urban R, Mariano N, Rahal JJ. Carbapenem-resistant Escherichia coli harboring Klebsiella pneumoniae carbapenemase beta-lactamases associated with long-term care facilities. Clin Infect Dis 2008, 46:e127-130. 10.1086/588048, 18419424.
64. Tsakris A, Poulou A, Kristo I, Pittaras T, Spanakis N, Pournaras S, Markou F. Large dissemination of VIM-2 metallo-β-lactamase-producing Pseudomonas aeruginosa causing healthcare-associated community-onset infections. J Clin Microbiol 2009, 47:3524-3529. 2772580, 19776233, 10.1128/JCM.01099-09.